Anavex Life Sciences (NASDAQ:AVXL) Price Target Raised to $42.00 at HC Wainwright

Anavex Life Sciences (NASDAQ:AVXL) had its target price boosted by HC Wainwright from $40.00 to $42.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday.

Anavex Life Sciences Stock Performance

NASDAQ AVXL opened at $12.56 on Thursday. The stock has a market capitalization of $1.07 billion, a P/E ratio of -25.12 and a beta of 0.73. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44. The stock has a fifty day moving average of $8.16 and a 200-day moving average of $6.36.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. Equities research analysts forecast that Anavex Life Sciences will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anavex Life Sciences

Several hedge funds have recently added to or reduced their stakes in AVXL. Nwam LLC acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth about $5,172,000. Renaissance Technologies LLC boosted its stake in Anavex Life Sciences by 483.8% during the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 386,537 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in Anavex Life Sciences during the second quarter valued at approximately $346,000. Barclays PLC increased its stake in Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after purchasing an additional 64,101 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Anavex Life Sciences by 2.8% in the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after purchasing an additional 51,946 shares during the period. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.